Abstracts Archive - Page 2376 of 2605 - ACR Meeting Abstracts

Abstract Number: 823 • 2013 ACR/ARHP Annual Meeting
Activation Of Liver X Receptors Inhibits Experimental Fibrosis By Interfering With Interleukin-6 Release From Macrophages
Christian Beyer¹, Jürgen Beer¹, Katrin Palumbo-Zerr¹, Pawel Zerr¹, Alfiya Distler¹, Clara Dees¹, Louis E. Munoz¹, Gerhard Krönke¹, Oliver Distler², Steve Anderson³, Georg A. Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Lexicon Pharmaceuticals Inc., The Woodlands, TX, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Liver X receptors (LXRs) are orphan nuclear receptors with emerging roles in metabolic and autoimmune diseases. Here, we investigated the role of LXRs in…
Abstract Number: 824 • 2013 ACR/ARHP Annual Meeting
Bosentan Improves Vascular Abnormalities In Endothelial Cell-Specific Fli1 Knockout Mice By Increasing The DNA Binding Ability Of Fli1 – a Possible Mechanism Explaining The Effect Of Bosentan On Scleroderma Vasculopathy
Kaname Akamata¹, Yoshihide Asano¹, Takashi Taniguchi¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Maria Trojanowska² and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although there…
Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Tatjana Mallano¹, Katrin Palumbo-Zerr¹, Christian Beyer¹, Clara Dees¹, Jingang Huang¹, Tsonwin Hai², Georg A. Schett³ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²The Ohio State Biochemistry Program, The Ohio State University, Columbus, USA, Colombus, OH, ³Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…
Abstract Number: 826 • 2013 ACR/ARHP Annual Meeting
The Value Of History and Physical Examination Findings In The Diagnosis Of Symptomatic Meniscal Tear Among Middle-Age Subjects With Knee Pain
Jeffrey N. Katz¹, Yan Dong², John Wright³, Stephanie Chen⁴, Scott Martin⁵, Laurel Donnell-Fink⁵, Benjamin N. Rome² and Elena Losina², ¹Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, ⁴Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Clinicians often rely on mechanical symptoms (e.g. clicking, catching, popping, giving way) and tests such as the McMurray sign in the diagnosis of symptomatic…
Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis
Nina Brodin^1,2, Malin Lohela Karlsson³, Emma Swärdh² and Christina H. Opava⁴, ¹Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, ²Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, SE 14183 Huddinge, Sweden, ³Institute of Environmental Medicine (IMM), Intervention and Implementation Research Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Neurobiology, Care Sciences and Society, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden
Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…
Abstract Number: 788 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients
Francisco Ortiz-Sanjuan¹, Ricardo Blanco², Javier Narvaez³, Esteban Rubio Romero⁴, Alejandro Olivé⁵, Santos Castañeda⁶, Adela Gallego Flores⁷, M. Victoria Hernández⁸, Cristina Mata¹, Inmaculada Ros Vilamajo⁹, Alberto Sifuentes Giraldo¹⁰, M Caracuel¹¹, Mercedes Freire¹², Catalina Gómez Arango¹³, José Llobet¹⁴, Sara Manrique Arija¹⁵, Carlos Marras¹⁶, Concepcion Moll Tuduri¹⁷, Chamaida Plasencia Rodriguez¹⁸, Rosa Roselló¹⁹, Ana Urruticoechea²⁰, Maria Luisa Velloso Feijoo²¹, Javier Loricera¹, Vanesa Calvo-Rio¹ and Miguel A González-Gay²², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Hospital Marques de Valdecilla, Santander, Spain, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de Mérida, Mérida, Spain, ⁸Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁹Hospital Son Llàtzer, Palma de Mallorca, Spain, ¹⁰Rheumatology, H Ramón y Cajal, Madrid, Spain, ¹¹Rheumatology., Hospital de Córdoba., Córdoba, Spain, ¹²Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹³HU Basurto, Bilbao, Spain, ¹⁴H Sant Pau, Barcelona, Spain, ¹⁵HRU Carlos Haya, Málaga, Spain, ¹⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁷Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, ¹⁸HU La Paz, Madrid, Spain, ¹⁹H San Jorge, Huesca, Spain, ²⁰Hospital Can Misses, Ibiza, Spain, ²¹H Valme, Sevilla, Spain, ²²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard immunosuppressive drugs and it may require biological therapy. Tocilizumab (TCZ) has demonstrated efficacy in clinical…
Abstract Number: 789 • 2013 ACR/ARHP Annual Meeting
Sirolimus Plus Prednisone For Erdheim-Chester Disease: A Pilot Trial
Davide Gianfreda¹, Federico Alberici², Maricla Galetti³, Maria Nicastro³, Carlo Buzio⁴ and Augusto Vaglio⁵, ¹University of Parma, Parma, Italy, ²Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, ³Nephrology University of Parma, Parma, Italy, ⁴Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, ⁵Unit of Nephrology, University Hospital of Parma, Parma, Italy
Background/Purpose: Erdheim-Chester disease (ECD) is an extremely rare form of non-Langerhans cell histiocytosis. The pathogenesis of ECD is unclear: while most authors suggest the hypothesis…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 791 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish
Hermine I. Brunner¹, Nicolino Ruperto², Zbigniew Zuber², Rubén J. Cuttica³, Ricardo Xavier², Inmaculada Calvo², Nadina Rubio², Ekaterina Alekseeva², Vyacheslav Chasnyk⁴, Jose Chavez², Gerd Horneff², Violetta Opoka-Winiarska², Pierre Quartier⁵, Alberto Spindler⁶, Caroline Keane⁷, Kamal N. Bharucha⁸, Jianmei Wang⁹, Daniel J. Lovell¹, Alberto Martini² and Fabrizio De Benedetti¹⁰, ¹PRCSG, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁴Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ⁵Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ⁶PRINTO, Genoa, OH, Italy, ⁷Roche, Welwyn Garden City, United Kingdom, ⁸Genentech, South San Francisco, CA, ⁹Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹⁰Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Efficacy and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, were previously demonstrated at week 40 of CHERISH, a phase 3 trial in patients…
Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Maja Bulatovic Calasan¹, Ethan den Boer², Maurits C.F.J. De Rotte³, S.J. Vastert⁴, Sylvia Kamphuis⁵, Robert De Jonge³ and Nico M. Wulffraat⁶, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁶Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…
Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Aileen L. Pangan⁴, Kristina Unnebrink⁵ and Jaclyn K. Anderson⁴, ¹Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²Pediatric Rheumatology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…
Abstract Number: 794 • 2013 ACR/ARHP Annual Meeting
Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors
Melissa L. Mannion¹, Fenglong Xie², Jeffrey R. Curtis³ and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The pharmacologic management of JIA has changed dramatically with the advent of tumor necrosis factor inhibitors (TNFi), but the impact of TNFi on medication…
Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Kirsten Minden¹, Klaus Tenbrock², Gerd Horneff³ and Hans-Iko Huppertz⁴, ¹Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ²University Aachen, Aachen, Germany, ³Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Prof. Hess Childrens Hospital, Bremen, Germany
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting
Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)
Michael H. Schiff¹, Lee S. Simon², Bruce Freundlich³, Jonathan Jaffe⁴ and Kaushik J. Dave⁵, ¹Rheumatology Division, University of Colorado, Denver, CO, ²SDG LLC Consulting, West Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁵Product Development, Antares Pharma Inc, Ewing, NJ
Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…
Abstract Number: 797 • 2013 ACR/ARHP Annual Meeting
Methotrexate Exposure Assessment In Routine Clinical Rheumatology Practice: Effect Of Dosing and Route Of Administration On Polyglutamate Levels
Roy A. Kaplan¹, Brigid Freyne², Derren Barken³ and Thierry Dervieux⁴, ¹Private Practice / Scripps Health, Encinitas, CA, ²Private Practice, Murietta, CA, ³Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: Large interpatient variability in Methotrexate (MTX) absorption and intracellular activation to methotrexate polyglutamates (MTXPGs) can explain, in part, the large spectrum of MTX response…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].